- Poster presentation
- Open Access
Systemic juvenile idiopathic arthritis in the republic of Bashkortostan
© Malievskiy; licensee BioMed Central Ltd. 2011
- Published: 14 September 2011
- Juvenile Idiopathic Arthritis
- Rheumatic Disease
- ILAR Criterion
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. In the structure of JIA, systemic arthritis makes 10 – 15 %. Being one of the variants of JIA it is defined as a heterogeneous disease.
To analyze the course, treatment and outcome of systemic JIA in children of the Republic of Bashkortostan (Russia).
Monocyclic disease course, patients had only one attack.
Polycyclic disease course was characterized by recurrent episodes of remission without medication.
Chronic persistent course, patients had extended poly-arthritis with or without systemic features.
We observed 33 boys and 23 girls. Mean age of the patients was 14.5 years (range 2.1-22.3 years). The mean age at diagnosis was 4.9 years (range 0.9-14.2 years). Mean disease duration was 9.6 years. 12 (21.4%) patients had monocyclic disease course, 15 patients (26.8%) had polycyclic disease course, and 29 patients (51.8%) had chronic persistent course. All the patients took non-steroidal anti-inflammatory drugs and oral prednisolone (0.7 – 1.0 mg/kg/day). 41 patients (73.2%) took intravenous methylprednisolone (20 -30 mg/kg/day) during three consecutive days. All the patients took disease-modifying anti-rheumatic drugs, including methotrexate (100 %) and cyclosporine A (17 patients, 30.3 %). Anti-TNF agents were used in three patients, but without any effect. In four patients some positive effect was reached by taking tocilizumab. Complications: structural injury (30 cases, 53.6%), growth retardation (22 cases, 39.3%), osteoporosis (36 cases, 64.3%), amiloidosis (3 cases, 5.3%).
Despite of similarity of clinical manifestations in debut of systemic arthritis in most patients, disease course considerably differs on different patients. Prognosis and outcome of disease may vary from “recovery” to “hard life-threatening after-effect”.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.